Type 2 Inflammation and Asthma in Children: A Narrative Review
The Journal of Allergy and Clinical Immunology: In Practice · 2024-09 · 12 (9) · 2310-2324
DOI: 10.1016/j.jaip.2024.06.010 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2024-09. Verfasst von Nikolaos G Papadopoulos und 9 weiteren Autor:innen. Beteiligte Einrichtung: Allergy and Clinical Immunology Unit, Second Pediatric Clinic, University of Athens, Athens, Greece; Lydia Becker Institute of Immunity and Inflammat…. Hauptthemen laut MEDLINE: Asthma, Inflammation. Die Arbeit wurde bisher 60-mal zitiert (Crossref) und nennt 135 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Regeneron Pharmaceuticals Inc, Sanofi US.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Increased understanding of the underlying pathophysiology has highlighted the heterogeneity of asthma and identified that most children with asthma have type 2 inflammation with elevated biomarkers, such as blood eosinophils and/or fractional exhaled nitric oxide. Although in the past most of these children may have been categorized as having allergic asthma, identifying the type 2 inflammatory phenotype provides a mechanism to explain both allergic and non-allergic triggers in pediatric patients with asthma. Most children achieve control with low to medium doses of inhaled corticosteroids. However, in a small but significant proportion of children, asthma remains uncontrolled despite maximum conventional treatment, with an increased risk of severe exacerbations. In this review, we focus on the role of type 2 inflammation and allergic processes in children with asthma, together with evidence of the efficacy of available treatment options for those who experience severe symptoms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Allergy and Clinical Immunology Unit, Second Pediatric Clinic, University of Athens, Athens, Greece; Lydia Becker Institute of Immunity and Inflammation, The University of Manchester, Manchester, United Kingdom. Electro…
- Division of Allergy, Immunology and Pulmonary Medicine, Monroe Carell Jr Children's Hospital at Vanderbilt University Medical Center, Nashville, Tenn.
- Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, Wis.
- University Lille, CHU Lille, Pediatric Pulmonology and Allergy Department, Hôpital Jeanne de Flandre, Lille, France.
- Department of Pediatrics, Harvard Medical School, Boston, Mass; Department of Allergy and Immunology, Boston Children's Hospital, Boston, Mass.
- Section of Pediatric Pulmonary and Sleep Medicine, Breathing Institute, Department of Pediatrics, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, Colo.
Förderung
- Regeneron Pharmaceuticals Inc
- Sanofi US
Zitieren
APA
Papadopoulos, N. G., Bacharier, L. B., Jackson, D. J., Deschildre, A., Phipatanakul, W., Szefler, S. J., Gall, R., Ledanois, O., Jacob-Nara, J. A., & Sacks, H. (2024). Type 2 Inflammation and Asthma in Children: A Narrative Review. The Journal of Allergy and Clinical Immunology: In Practice, 12(9), 2310-2324. https://doi.org/10.1016/j.jaip.2024.06.010
Vancouver
Papadopoulos NG, Bacharier LB, Jackson DJ, Deschildre A, Phipatanakul W, Szefler SJ, et al. Type 2 Inflammation and Asthma in Children: A Narrative Review. The Journal of Allergy and Clinical Immunology: In Practice. 2024;12(9):2310-2324. doi:10.1016/j.jaip.2024.06.010
BibTeX
@article{Papadopoulos2024,
author = {Papadopoulos, Nikolaos G and Bacharier, Leonard B and Jackson, Daniel J and Deschildre, Antoine and Phipatanakul, Wanda and Szefler, Stanley J and Gall, Rebecca and Ledanois, Olivier and Jacob-Nara, Juby A and Sacks, Harry},
title = {Type 2 Inflammation and Asthma in Children: A Narrative Review},
journal = {The Journal of Allergy and Clinical Immunology: In Practice},
year = {2024},
volume = {12},
number = {9},
pages = {2310--2324},
doi = {10.1016/j.jaip.2024.06.010}
}
EUVIMED